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Renal functional reserve in treated and untreated hypertensive rats.
Renal functional reserve (renal response to protein loading, RFR) has
been suggested as a method to verify the presence of hyperfiltration.
This study was designed to evaluate the role of RFR as an indicator of
increased glomerular capillary hydrostatic pressure in short-term
treated and untreated rats with two-kidney, one-clip Goldblatt hyper-
tension. One month after placing a silver clip, micropuncture studies
were performed on the unclipped kidney. Normal rats and three groups
of clipped rats [untreated group (HYP), a group treated with captopril(CEI) and a group treated with verapamil (VER) 5 days before the
micropuncture studies] were studied. Glomerular hemodynamics and
proximal tubular reabsorption were measured in control period and
during intravenous administration of glycine (G). In normal rats, 0
produced afferent and efferent dilation, increases in single nephron
plasma flow (SNPF) and single nephron glomerular filtration rate
(SNGFR) of 24%. Systemic hypertension in HYP rats was associated
with increases in transcapillary pressure gradient (P) and SNGFR. In
this hyperfiltration state, infusion of G did not modify SNGFR of SNPF
defining loss of RFR. The antihypertensive treatment was equally
effective in normalizing MAP and P in CEI and VER, but only CEI
rats responded to 0 with a 20% increase in SNGFR due to an increase
in P. The most striking findings were that loss of RFR in both HYP and
VER rats was associated with a significant decrease in absolute and
proximal fractional reabsorption. We conclude that: I) loss of RFR is
not always associated with the presence of glomerular hypertension;
and 2) decreases in proximal tubular reabsorption strongly correlate
with loss of RFR, suggesting an important role for tubular function in
the glomerular hemodynamic response to intravenous amino acid
infusion.
In early 1980, Hostetter andcoworkers suggested that hyper-
filtration, that is, increased glomerular capillary pressure and
flow, constitutes a major risk factor for the progression of renal
disease [1]. Since this initial observation, experimental data
obtained in models of renal ablation, DOCA-salt hypertension
and experimental diabetes have supported the role of hyperfil-
tration as a risk factor in the development of glomerular
sclerosis [2—5]. The role of hemodynamic factors in the progres-
sion of experimental renal disease generated great interest
among clinicians with respect to the applicability of these
concepts in the progression of renal disease in humans. In 1983,
Bosch and coworkers suggested that evaluation of the renal
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functional reserve (renal response to a protein load) could be
used to identify the presence of hyperfiltration in humans [6, 7].
Several groups of investigators have utilized renal functional
reserve to evaluate the presence of hyperfiltration in conditions
such as glomerulonephritis, renal transplant, solitary kidney
and diabetes mellitus [8—13]. Although examination of RFR may
be critical to the detection and treatment of patients with renal
disease, very few experimental data have been provided to
establish the value of RFR as a valid index of the presence of
hyperfiltration or other potential factors contributing to pro-
gression of renal disease [14, 15].
Intravenous administration of a mixture of amino acids or of
a single amino acid such as glycine provides an excellent
method to test RFR in rats [16, 171. Previous micropuncture
studies on the contralateral kidney of two-kidney, one-clip
Goldblatt hypertensive rats have demonstrated that hyperfiltra-
tion correlated with lack of response to amino acid infusion
[141. We have utilized this model of hypertension to further
characterize RFR and to answer the following questions: What
are the glomerular and tubular responses to amino acid infusion
in normal and physiopathologic conditions? What is the effect
of short term treatment with two widely utilized antihyperten-
sive agents (captopril and verapamil) on RFR? Does normaliza-
tion of systemic or glomerular capillary pressure restore RFR?
Methods
The studies were performed in thirty male Munich-Wistar
rats (180 to 220 g body wt) obtained from Simonsen Laborato-
ries (Gilroy, California, USA). One group of normal control rats
(NOR, N = 6) and three groups of two-kidney, one-clip (2K1C)
Goldblatt model rats were studied. Rats of the latter three
groups were prepared under methohexital sodium anesthesia by
placing a 0.2 mm slit width silver clip on the right renal artery.
Systolic blood pressure was measured weekly in awake clipped
animals via tail cuff method with a Narco Scientific electro-
sphygmomanometer (Narco Biosystems, Houston, Texas,
USA) and a heated animal restraining cage. Clipped rats with
systolic blood pressure < 140 mm Hg (30% of the total) were
excluded from the study.
Four to five weeks after clipping, hypertensive rats were
randomly divided into the three different groups (N = 6 per
group); hypertensive untreated rats (HYP), and hypertensive
rats which received either captopril (500 mg/liter in drinking
water, CEI) or verapamil (1 g/liter in drinking water, VER) five
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days before micropuncture. Both solutions were daily prepared
and stored in wrapped bottles in order to avoid potential
deteriorating effects of the light.
Micropuncture studies
The animals were maintained with ad libitum access to tap
water and normal rat chow until the morning of the experiment.
Rats were anesthetized with mactin (BKY, Constance, Ger-
many) 10 mg/100 g body wt i.p. and placed on a temperature-
regulated micropuncture table. Rats were surgically prepared
according to standard procedures. Briefly, the rats underwent
tracheostomy and cannulation of the left jugular vein, left
femoral artery, left ureter and bladder. The left unclipped
kidney was exposed via a flank incision and placed in a Lucite
cup. The cup surrounding the kidney was packed with cotton
and 2% agar and the surface was covered with heated (37°C)
NaCl-NaHCO3 solution. The femoral artery catheter was used
for periodic blood samples and monitoring of the mean arterial
pressure (MAP) with a transducer (model P23db, Statham
Instruments, Gould Division, Hato Rey, Puerto Rico) and
recorded on a Statham chart recorder. All studies were per-
formed in euvolemic state by infusing 1% body wt donor plasma
over a one hour period followed thereafter by 0.15% body wt
donor plasmalhr. All rats also received two additional infusions
of NaCI-NaHCO3 solutions, one containing [3H] inulin at a rate
of 100 pCiIhr in a volume of 0.8 ml/hr; the other one (1.4 ml/hr)
served as control for the glycine solution infused during the
second period. Both solutions were initiated 60 minutes before
the first micropuncture measurement and maintained through-
out the experiment.
Two period studies were conducted in each rat. All determi-
nants of glomerular ultrafiltration and nephron filtration rate
were measured in a euvolemic control period and after glycine
infusion. Hydrostatic pressures in the glomerular capillaries
(PG), urinary space (P5), and efferent arterioles (HPE) were
measured with a glass micropipette (1 to 3 m in external tip
diameter, filled with 1.2 M saline) in series with a servo-nulling
pressure measurement device (1PM, San Diego, California,
USA) as previously described [181. Glass pipettes of 13 to 16
m were used to collect at least three efferent arteriolar blood
samples for determination of efferent protein concentration
(CE) and these were bracketed by two collections from femoral
artery for measurement of afferent protein concentration (CA).
Late surface segments of proximal tubules were identified by
intratubular injection of diluted FD & C dye contained in a
pipette of 3 to 5 sm o.d. and, therefore, four to five timed
tubular fluid collections were randomly obtained from these
sites. All measurements required less than 60 minutes. After
completion of euvolemic control observation (C), 20 gldl gly-
cine (G) in isotonic NaCI-NaHCO3 solution was infused at
approximately 1.4 ml/hr; after 30 minutes, all measurements
were repeated during continuous glycine infusion and required
about 60 minutes to complete. Urine was collected in pre-
weighed containers under oil and period plasma samples were
obtained for [3H] inulin concentration to compute whole kidney
GFR and SNGFR.
In a second protocol two additional groups of normal and
hypertensive untreated rats (N 3 per each group) were used
to define late proximal tubular and plasma glycine concentra-
tion using similar methods previously described by this labora-
tory for glucose measurement [19]. After a control period of
about 60 minutes, glycine (20 g/dl solution) plus ['4C] glycine
(ICN, Irvine, California, USA) was infused at a rate 1.4 mI/hr
sufficient to deliver 100 to 120 J.LCi/hr. Thirty minutes after
initiating glycine infusion a new set of tubular fluid samples was
obtained over a period of one hour. Tubular fluid volumes and
total ['4C] glycine in tubular fluid were determined. ['4C1
glycine cpm were determined in the glycine solution (GLYS)
and in plasma ([14C]GLY); glycine plasma concentration
(GLY) was derived from the formula: ['4C]GLY5/20 = ['4C]
GLY/GLY. With these methods late proximal tubule fluid-to-
plasma 1'4C1 glycine ratios and absolute plasma and tubular
fluid glycine concentrations can be readily defined (TF/P ['4C]
glycine x plasma glycine = late proximal glycine concentra-
tion).
Analytic methods
[3H] Inulin activity in plasma, urine and tubular fluid was
monitored on a model 2425 Packard liquid scintillation counter
(Packard Instruments; Downers Grove, Illinois, USA).
SNGFR, GFR, the ratio of tubular fluid-to-plasma inulin activ-
ity (TF/P), fractional reabsorption (FR) and absolute proximal
reabsorption (APR) were determined as described in previous
studies from this laboratory [201. Proteiin concentration in
systemic and efferent arteriolar plasma samples was measured
by a microadaptation of the Lowry protein method [21].
Calculations
Superficial nephron filtration fraction (SNFF), SNPF, af-
ferent arteriolar resistance (AR), efferent ai-teriolar resistance
(ER) and oncotic pressure (ir) from protein concentration were
calculated as described in previous publications [18, 22].
Changes in SNPF modify the profile of effective filtration
pressure (EFP) along the glomerular capillary by affecting the
rate at which protein is concentrated and the rate of rise in ii
along x. The SNGFR can therefore be determined as follows:
SNGFR = LpA x EFP, where LpA is the glomerular ultrafil-
tration coefficient, which in turn is a product of the hydraulic
conductivity (Lp) of the glomerular membrane and A, the total
filtering surface area of the glomerular capillary. LpA is com-
puted utilizing an iterative procedure as previously described
[23].
Statistics
Statistical significance of measurements between the two
periods was evaluated by either unpaired or paired 1-test,
depending on whether there were multiple or single values
obtained per period [24], Tukey multiple comparison analysis
was also performed to obtain statistical significance between
groups of animals. The level of statistical significance was
defined as P < 0.05. All results are expressed as means SEM.
Results
Effects of renal artery clip application and treatment of
hypertension
Awake systolic blood pressure (ABP) prior to initiation of
antihypertensive treatment did not differ among the three
groups of clipped rats (158.3 2.1 mm Hg in HYP, 157.5 7,8
mm Hg in CEI and 160.0 2.9 mm Hg in VER). After four days
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Table 1. Glomerular hemodynamics before (C) and after (G) glycine in normal rats (NOR), two-kidn
rats (CEI) and verapamil treated rats (VER)
ey, one-clip rats (HYP), captopril treated
LpA
MAP
mm
Hg
GFR
mit
mm Hct
SNGFR SNPF ITA ITE P3 Pus 1P HP,, EFP
AR ER senc
X mm
dyne sec. cm5 Hgni/mm SNFF mm Hg
NOR-C 117.9 1,15 0.50 41,5 116.5 0.36 15,9 30.9 46.6 11.8 34.8 16.9 11.8 24.0 12.8 0.067
NOR-G 121.7 132b 0.50
±1.4 ±2.9 ±0.02 ±1.1 ±1.1 ±1.2 ±1.2
51.1" 1424" 0.36 14.9 29.7 51.0 18.91
±0.9
32.1
±0.7
219b
±2.2
10.3
±0.8 ±0.4 ±0.01
209b.g l05" 0.105
±2.4 ±0,04 ±0.01 ±2.7 ±7,7 ±0.03 ±1.1 ±1.8 ±2.2 ±1.6 ±1.6 ±0.9 ±3.1 ±1.1 ±0.4 ±0.02
HYP-C 166.7e 1.53c 0.51 52.7e 134.7 0.39 14.6 31.2 59.6c 13.1 46.5c 18.4 23.2e 32.7c 15.0 0.041
±8.1 ±0.1 ±0.01 ±1.9 ±6.9 ±0.03 ±0.9 ±0.9 ±2.0 ±1.1 ±1.8 ±0.5 ±2.9 ±2.3 ±1.2 ±0.01
HYP-G 166,2c 1.60 0.49 47.3 139.8 0.35 13.7 26.8 57.2 16.2 41.0" 21.1" 20.7 35.le 14,9e 0040d
±11.2 ±0.1 ±0.01 ±2.1 ±14 ±0,04 ±0.8 ±2,0 ±2.5 ±1.6 ±1.7 ±0.8 ±2.4 ±2.6 ±1.4 ±0.01
CEI-C 107.8 1.04 0.50 43.6 164.2 0.32 13.7 25.5 13.8 17.5 11.2 19.5 0.083
±4.1 ±0.07 ±0.01 ±1.8 ±18 ±0.05 ±0.4 ±2.7 ±1.4 ±1.0 ±0.7 ±0.5 ±3.0 ±1.9 ±1.0 ±0.01
CEI-G 1213b 122b 0.48 50,1E 157.0 0.35 12.3" 23.9 48,7" 15.5 33.2" 20.0 14.9 22.1 10.1 0.065
±3.9 ±0.09 ±0.01 ±1.9 ±13 ±0.03 ±0.3 ±2.0 ±1.7 ±1.1 ±1.3 ±1.1 ±2.6 ±1.8 ±0.8 ±0.01
VER-C 119.6 1.15 0.50 47.9 122.1 0.42 12.8 29.9 49.5 13.1 36.4 20.9c 15.7 24.4 15.1 0.061
±2.6 ±0.09 ±0.01 ±2.1 ±8.5 ±0.05 ±0.5 ±3.2 ±2.2 ±0.6 ±2.2 ±0.6 ±2.9 ±1.6 ±2.0 ±0.01
VER-G 116.8 1.21 0.48 44.0 102.4e 0.45 11.1 26.9 50.4 18.2" 32.2 20.8 13.4 29.5 16.1 0.077
±2.6 ±0.13 ±0.03 ±2.5 ±6.5 ±0.02 ±0.9 ±1.9 ±2.2 ±1.7 ±1.5 ±1.3 ±3.0 ±3.6 ±1.4 ±0.02
All values expressed as mean ± scm
b By Student's (-test, P < 0.05 vs. C
By Tukey test, P < 0.05 vs. other groups
d By Tukey test, P < 0.05 vs. NOR
C By Tukey test, P < 0.05 vs. NOR and CE!
By Tukey test, P < 0.05 vs. NOR and VER
g By Tukey test, P < 0.05 vs. HYP and VER
of treatment ABP was significantly decreased (P < 0.001) to a
similar extent in both CEI and VER group (102.5 ± 2.5 mm Hg
and 111.6 ± 4.9 mm Hg, respectively).
At the time of the micropuncture experiment body weight
was slightly but significantly lower (P < 0.05) in VER group
(218.3 ± 4.9 g) compared with NOR (238.8 ± 5.6 g), HYP(242. 1
± 4.7 g) and CEI groups (251.3 ± 3.3 g).
Micropuncture data are reported in Table 1. The increased
MAP observed in hypertensive untreated animals compared
with the other three groups (P < 0.001) was associated with
increment in left kidney GFR (1.53 mI/mm, P < 0.05 vs. other
groups). Also the basal SNGFR was increased in this group
(52.7 ± 1.9 nl/min) compared with NOR group (41.5 ± 1.4
ni/mm, P < 0.001) and CE! group (43.6 ± 1.8 nI/mm, P <
0.005). The higher filtration rate in HYP was due to significant
increases in both glomerular capillary hydrostatic pressure, G
(59.6 ± 2 mm Hg, P < 0.005 vs. other groups) and glomerular
hydrostatic pressure gradient, 1P (46.5 ± 2 mm Hg, P < 0.001
vs. other groups). Preglomerular resistances (AR) were signif-
icantly elevated in HYP group (P <0.005 vs. other groups) but
did not achieve a level sufficient to prevent the transmission of
increased systemic high blood pressure to the glomerulus.
Captopril administration resulted in a lower MAP compared
with HYP group, values not different from MAP values in NOR
and VER group. CE! produced an increase in SNPF (164.2 ± 18
nI/mm, P < 0.05 vs. NOR and VER group) associated with a
significant reduction in both afferent and efferent glomerular
resistances (P < 0.05 vs. HYP). Furthermore, the CEI group
demonstrated a lower basal value of iP (28.9 ± 0.7 mm Hg)
when compared with HYP (46.5 ± 1.8 mm Hg, P < 0.001) and
VER group (36.4 ± 2.2 mm Hg, P < 0.05), the latter only
numerically different from the value measured in NOR group.
The decrease in AP was likely responsible for the reduction of
SNGFR observed in CE! when compared with HYP (P <
0.005). In this group, in fact, at least 50% of the rats exhibited
filtration pressure disequilibrium, a condition in which changes
of zP play a more important role as determinant of SNGFR.
As mentioned above, verapamil administration in hyperten-
sive rats resulted in a significant decrease in MAP. The reduc-
tion in MAP was associated with afferent arter olar vasodilation
(AR: 24.4 ± 1.6, P <0.005 vs. HYP). In the VER group Gand
P were also reduced to a level not different from NOR but,
significantly higher than values in the CE! group (P < 0.05).
SNGFR was numerically higher than the values detected in
NOR and CE! but not statistically different either from them or
the HYP group.
The ultrafiltration coefficient, LpA, was not different in any
of the four groups. No differences were detected in the basal
value of afferent and efferent protein concentration and, conse-
quently, in oncotic pressures. Also hematocrit (Hct) was not
affected either by the induction of hypertension or by the two
different treatments.
Effects of glycmne infusion on glomerular dynamics
Micropuncture data are depicted in Table 1 and percentage
changes in SNGFR, SNPF, tP and LpA during glycine infusion
are shown in Figure 1. Glycine infusion in normal rats induced
a significant rise in GFR; whole-kidney GFR rose 15% (P < 0.05
vs. C) and SNGFR 24% (P < 0.001 vs. C). The rise in SNGFR
was due to a significant increase in SNPF. SNPF changed in the
same proportion as SNGFR, 22% (P < 0.001 vs. C); therefore
filtration fraction did not change. The renal vasodilatory re-
sponse to glycine was characterized by a reduction in both
afferent and efferent glomerular resistances (P < 0.05 and P <
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0.001 vs. C, respectively). The numerical increase in PG was
neutralized by the rise in P (P < 0.05 vs. C), and no change
was detected in zP.
In hypertensive untreated rats, the presence of hyperfiltration
and glomerular hypertension was associated with complete
elimination of the response to glycine, whole-kidney GFR and
SNGFR remained unchanged. P was significantly decreased
(P < 0.05 vs. C) because of a simultaneous slight decrease in G
in the presence of an increase in Pus. Since glomerular resis-
tances did not decrease and remained higher after glycine (P <
0.005 vs. NOR and CE! same period), no change was observed
in SNPF. In this group LpA was not modified but was signifi-
cantly lower when compared with normal rats (P < 0.05 vs.
NOR-G).
A significant increase in both GFR (+ 17%, P < 0.02 vs. C)
and SNGFR (+ 20%, P < 0.05 vs. C) after glycine infusion was
obtained in hypertensive rats which received captopril treat-
ment. The mechanism by which the filtration rate was elevated
in this group was completely different from NOR. CE! rats
exhibited a higher G (P < 0.02 vs. C) and consequently P
(+ 18%, P < 0.01 vs. C) secondary to the change observed in
systemic blood pressure. MAP rose from 108 4 to 121 4mm
Hg (P < 0.05) during glycine infusion. Transcapillary hydro-
static pressure gradient resulted, therefore, as the main driving
force to increase renal function in this group. Glomerular
resistances did not vary and SNPF was not modified after
glycine; similarly, no changes were detected in LpA.
In contrast to CE!, glycine infusion in verapamil treated rats
did not produce any significant variation in GFR or SNGFR,
designating loss of RFR. In this group all the determinants of
glomerular ultrafiltration remained unchanged during the sec-
ond period.
Values for tubular fluid to plasma inulin ratio, absolute and
fractional proximal tubular reabsorption are depicted in Table
2. Glycine administration in NOR rats produced a significant
increase in SNGFR, a numerical increase in APR and did not
modify FR. In contrast, infusion of glycine in HYP was
associated with a remarkable reduction in proximal tubular
reabsorption as indicated by the reduction in APR, TF/P (P <
0.001 vs. C) and fractional reabsorption, (FR; P < 0.001 vs. C);
the latter values were the lowest value among the four groups (P
Table 2. Tubular effects of glycine infusion in normal rats (NOR),
two-kidney, one-clip rats (HYP), captopril (CEL) and verapamil
(VER) treated ratsa
APR
TF/P ni/mm FR
NOR-C 1.52 0.04 14.2 0.8 0.34 0.01
NOR-G 1.52 0.06 17.7 1.8 0.32 0.02
HYP-C 1.63 0.1 18.2 1.4 0.35 0.03
HYP-G 1.15 01b.c 6.9 19b,d 0.11 003b.c
CEI-C 1.56 0.05 15.1 1.2 0.35 0.02
CEI-G 1.48 0.1 14.5 1.5 0.29 0.03
VER-C 1.58 0.03 17.4 0.9 0.36 0.01
VER-G 1.42 006b 12.3 15b 0.27 003b
a All values expressed as mean SEM
b By Student's 1-test, P < 0.05 vs. C
C By Tukey test, P < 0.05 vs. other groups
' By Tukey test, P < 0.05 vs. NOR and CEL
< 0.001 vs. other groups, same period). In CE! treated rats,
glycine increased SNGFR, and as observed in control rats,
there was no significant modification in absolute and fractional
proximal reabsorption after glycine. The VER group behaved
similarly to the HYP group, in the sense that the lack of
response to glycine was associated with significant decrease in
APR (P < 0.001 vs. C) and FR (P < 0.02 vs. C).
'4C-glycine was used to determine plasma and tubular con-
centrations of glycine in normal and untreated hypertensive
rats. As shown in Table 3, plasma concentrations were similar
in both groups, 135 8 and 124 9 mgldl in normotensive and
hypertensive rats, respectively. Tubular concentration of gly-
cine was determined in 17 nephrons from each of the two
groups. Tubular concentrations were significantly higher in
normotensive compared to hypertensive rats. No specific os-
motic effect of glycine was identified in any of the two groups
since TFIP glycine was below 1. Interestingly, filtered load of
glycine and proximal glycine reabsorption were strikingly sim-
ilar between the two groups of rats (56 4 and 23 3 ng/min
in normotensive and 54 2 and 26 2 nglmin in hypertensive,
P > 0.05).
Discussion
This study was designed to evaluate if loss of RFR can
predict the presence of glomerular hypertension in rats with
*
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Fig. 1. Percentage changes in SNGFR, SNPF, P and
LpA during glycine administration. Data are shown as
mean SEM. By Tukey test, *O< 0.005 vs. HYP and
VER, < 0.05 vs. VER, A P < 0.05 vs. other
groups.
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Table 3. Plasma concentration of glycine (GLY), tubular glycine concentration (GLYJ, tubular fluid-to-plasma glycine
concentration (GLYTF/P), filtered load (GLYFL) and proximal reabsorption rate of glycine (GLYAPR) in normal (NOR) and two-kidney,
one-clip rats (HYP)
GLY GLY,
GLYTF/P
GLYFL GLYAPR
mg/dl ng/min
NOR 134.8 7.6 104.1 5.2 0,78 0.04 56.4 3.7 22.6 2.7
HYP 124.3 8.6 80.8 4.9' 0.66 0.03k' 54.0 2.4 26.1 1.8
a All values are expressed as mean SEMb By Student's r-test, P < 0.05 vs. NOR
untreated renovascular hypertension and after short term treat-
ment with two different antihypertensive agents, captopril and
verapamil. Our results demonstrate that in a normal rat, intra-
venous administration of glycine induces afferent and efferent
arteriolar vasodilation with subsequent increases in plasma flow
which leads to a significant increase in SNGFR. In rats with
systemic and glomerular hypertension, glycine infusion does
not modify SNGFR, defining loss of RFR. Our data agree with
previous data by Herrera-Acosta et al using a model of hyper-
tension with superimposed renal ablation in which these au-
thors demonstrated loss of RFR in rats with elevated iP [15].
Interestingly, an increase in SNGFR in the absence of changes
in iP does not blunt the normal response to proteins as shown
by Herrera-Acosta et a! in their normotensive renal ablated rats
in which SNGFR increased by 35% after glycine infusion in
spite of a significant increase in baseline SNGFR when com-
pared to normal unmanipulated rats. The other model of exper-
imental hypertension in which RFR has been evaluated is the
spontaneously hypertensive rat (SHR) [25]. Baylis demon-
strated that in the prehypertensive as well as during the
hypertensive phases SHR exhibit no renal vasodilation after
glycine infusion. However, lower values for SNGFR in the
SHR, and what might be considered an elevated P value in
comparison to Munich-Wistar rats, preclude a more definitive
conclusion of the capacity of RFR to detect the presence of
glomerular hypertension in this experimental model.
Another goal of this study was to evaluate the effect of
antihypertensive treatment on the renal functional reserve.
Specifically, does loss of RFR in the presence of antihyperten-
sive treatment correlate with the presence of glomerular hyper-
tension? In 1987, studies by Dworkin and coworkers demon-
strated that decreasing systemic blood pressure in an
experimental model of hypertension was not sufficient to pre-
vent the development of glomerular sclerosis [26]. Indeed,
prevention of glomerular sclerosis required not only lowering
systemic blood pressure but also normalizing glomerular capil-
lary pressure. Mter this initial observation by Dworkin and
coworkers, studies have been performed by several investiga-
tors in different experimental conditions in order to characterize
the capacity of various antihypertensive agents to lower sys-
temic blood pressure and prevent the development of glomer-
ular sclerosis [27—31]. Unfortunately, the information provided
by all these studies has been far from clear with some agents
providing benefit under certain circumstances but not in others
limiting more general conclusions with regard to advantages of
specific agents. We decided to investigate if RFR could provide
a tool, easily accessible to the clinician, to indirectly evaluate
the presence of a risk factor such as glomerular hypertension or
a neurohumoral environment leading to progression of renal
disease. Captopril and verapamil are the two antihypertensive
agents that were evaluated because these agents are widely
used in clinical practice and both provide a good blood pressure
control in our experimental model.
Administration of captopril produced not only a reduction in
systemic blood pressure but significant changes in the determi-
nants of the glomerular ultrafiltration. The increase in plasma
flow during captopri! treatment is in agreement with previous
studies by Huang et al which demonstrated that acute admin-
istration of CEI in rats with two-kidney, one-clip Goldblatt
hypertension produces significant increases in plasma flow and
GFR in the unclipped kidney as a result of suppressing the
vasoconstrictor effect of angiotensin II [32, 33]. In the captopril
treated rats, intravenous administration of glycine was associ-
ated with significant increases in both GFR and SNGFR due to
increases in P instead of SNPF as in normal rats. The increase
in P resulted from a slight increase in systemic blood pressure
during glycine administration while afferent arteriolar resis-
tance remained unchanged, permitting changes in systemic
blood pressure to be transmitted to the glomerular capillary.
There is no clear explanation for the increase in blood pressure
during glycine infusion. The change in blood pressure seems
quite specific for this experimental model since we have repro-
duced these findings using a specific angiotensin II receptor
antagonist in the same model (unpublished observations). Fur-
thermore, we have not observed changes in blood pressure
during glycine administration in rats with experimental diabetes
treated with enalapril [34].
In contrast to the administration of CEI, normalizing both
systemic and glomerular capillary pressure with verapamil did
not restore RFR. These findings would suggest that the mech-
anism by which captopril and verapamil lower blood pressure
and glomertilar capillary pressure is quite different and may be
important to the response after glycine infusion. Since captopril
suppresses angiotensin II and by enhancing bradykinin produc-
tion increases endothelial-derived relaxing factor, there are two
possible mechanisms by which captopril can influence the renal
hemodynamics and the response to glycine [35—37]. Verapamil
acts as an afferent arteriole vasodilator and under certain
experimental conditions, such as the two-kidney, one-clip
model, increases plasma renin activity [38, 39]. The effect of
verapamil on the afferent arteriole may limit further vasodila-
tion during amino acid infusion as shown by Woods, Smith and
DeYoung [40].
The most striking results from our study were the changes in
proximal tubular reabsorption after glycine administration in
rats with loss of RFR. Disruption of glomerulo-tubular balance
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was evident in rats with loss of RFR (hypertensive rats and
verapamil treated rats) as evidenced by a significant decrease in
fractional reabsorption during glycine infusion. Captopril treat-
ment was associated with both an increase in GFR during
glycine and normal glomerulo-tubular balance as demonstrated
in normal rats. These findings suggest that disruption of gb-
merubo-tubular balance is strongly associated with the loss of
RFR. The mechanism responsible for the decrease in fractional
reabsorption in rats with loss of RFR is not readily apparent. A
specific osmotic effect of glycine on tubular reabsorption was
ruled out, since the tubular fluid to plasma ratio of glycine was
quite similar in both normotensive and hypertensive rats and
below one. Measurements of filtered load of glycine and prox-
imal glycine reabsorptive rate provided very interesting findings
in that both normotensive and hypertensive demonstrated sim-
ilar values for both of these parameters. However, the mecha-
nism by which each group of rats achieved a similar filtered load
is quite different. In hypertensive rats, the filtered load was
determined by an elevated SNGFR under baseline conditions,
while the normotensive rats achieved a similar filtered load
through a 23% increase in SNGFR when compared to control
values. Under these circumstances, one could speculate that
tubular reabsorption may be an important limiting modifier of
the renal response to proteins. Tubular reabsorption is normally
maintained during increases in filtered load of glycine to a
maximum level at which fractional reabsorption is still main-
tained. In contrast, in the presence of increased SNGFR in the
setting of two-kidney, one-clip rats, the increased filtered load
of amino acids could overwhelm tubular reabsorptive capacity
and result in a decreased fractional reabsorption.
The mechanism by which tubular reabsorption acts as a
modifier of the renal plasma flow response to proteins has not
been elucidated. Activation of the tububoglomerular feedback
system is certainly a logical possibility. Active participation of
the tubuloglomerular feedback system has been suggested in
the normal renal response to proteins [41]. The tubulogbomer-
ular feedback system is one of the intrarenal mechanisms
responsible for maintaining a balance between tubular reab-
sorption and glomerular filtration rate [42]. The tubulogbomer-
ular feedback system couples information obtained at the
macula densa with changes in afferent resistance, thereby
modifying intragbomerular pressure and flow to maintain gb-
merular filtration rate appropriate to the level of tubular reab-
sorption. To obtain significant increases in GFR, one must
postulate either a primary role of tububogbomerular feedback in
modifying the afferent resistances, or at least resetting of this
system, allowing the kidney to operate at a higher level of GFR.
Previous studies by Woods et a! have suggested a primary role
for tubuloglomerular feedback system in the renal response to
proteins [41]. Woods et a! postulated that increases in proximal
tubular sodium reabsorption through the sodium amino acid
co-transport would decrease sodium delivery to the macula
densa. This decrease in distal tubular sodium delivery would
decrease the afferent tubuloglomerular feedback signal, which
would be translated into a decrease in afferent resistance and an
increase in GFR. In support of their hypothesis, Woods et a!
demonstrated that complete suppression of tubuloglomerubar
feedback system, obtained by lowering renal perfusion pressure
or using the non-filtering kidney, inhibited the response to
amino acid infusion.
In contrast to the normal pattern, glycine delivery to a
proximal tubule operating at its maximum reabsorptive capacity
could result in significant decreases in proximal tubular reab-
sorption. The decrease in proximal tubular reabsorption leads
to an important increase in distal delivery capable of activating
the tubuloglomerular feedback system, resulting in afferent
constriction. Although changes in tubuloglomerular feedback
activity constitute a very attractive mechanism to explain both
the presence and absence of a renal vasodilatory response to
proteins, recent data from Brown and Navar cast some doubt
about this possibility [431. Indeed. Brown and Navar examined
the role of the tububoglomerular feedback system during amino
acid infusion in the dog by blocking distal delivery with a wax
block in the late proximal tubule. Placement of a wax block did
not prevent the normal increase in GFR during amino acid
infusion, suggesting that under normal condition the tubulo-
glomerular feedback system is not a major contributor to renal
vasodilation to protein load. Although the tubuloglomerular
feedback system may not be critical for normal response to
proteins, it remains possible that loss of RFR in the hyperten-
sive rat may be the result of tubu!ogbomerular feedback activa-
tion secondary to reductions in proximal reabsorption during
glycine infusion. Based on this scarce information, it is difficult
to draw definitive conclusions regarding the role of tubulo-
glomerular feedback system in the renal response to proteins,
and more studies will be required.
In summary, our study demonstrates that intravenous admin-
istration of glycine induces renal vasodilation and increases in
GFR. Under normal conditions proximal tubular reabsorption
increases to maintain glomerulo-tubular balance. Loss of the
normal vasodilatory response to proteins is associated with a
major reduction in proximal tubular reabsorption which proba-
bly participates actively in limiting the gbomerular response.
Finally, loss of renal functional reserve does not consistently
either correlate with or indicate the presence of gbomerular
hypertension.
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